Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

[1]  Jie Xiao,et al.  Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial , 2023, Journal of Hematology & Oncology.

[2]  K. Pratz,et al.  Recent advances in targeted therapies in acute myeloid leukemia , 2023, Journal of Hematology & Oncology.

[3]  A. Sun,et al.  Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study , 2022, Blood.

[4]  Mengya Zhong,et al.  Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia , 2022, Blood.

[5]  D. Nie,et al.  Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia , 2022, Blood.

[6]  Y. Ning,et al.  Phase 1 Dose Escalation Trial of Pegcrisantaspase in Combination with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia , 2022, Blood.

[7]  Nighat Shahbaz,et al.  Response to Hypomethylating Agents Plus Venetoclax in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome: Real World Data from a Developing Country , 2022, Blood.

[8]  Hongkun Wang,et al.  Venetoclax in Combination with Hypomethylating Agents Compared to Standard Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia , 2022, Blood.

[9]  P. Vyas,et al.  Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) , 2022, Blood.

[10]  H. Serve,et al.  Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial , 2022, Blood.

[11]  M. Konopleva,et al.  Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy , 2022, Blood.

[12]  Jie Xiao,et al.  Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia , 2022, Blood.

[13]  M. Konopleva,et al.  Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia , 2022, Blood.

[14]  Hong-jie Shen,et al.  CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia , 2022, Experimental Hematology & Oncology.

[15]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..